Drug design for Influenza A virus subtype H1N1

Abstract An outbreak of influenza A virus subtype H1N1, also known as swine flu, in Mexico was occurred in April 2009. To design drugs for treating this epidemic is urgency. In this study, we employed the new sequences (2009) to build the N1 simulation structure by homology modeling, which has been checked for high reliability by Verify Score and Ramachandran plot. The latest H1 homology model was employed from Chen's report. 365,602 compounds from NCI database have been screened by docking study of H1 and N1, respectively. And then, nine candidates were screened and suggested as potent dual target candidates from the docking studies. In our investigation, drug resistance was found by our molecular simulation in the new N1 modeling structure to oseltamivir. However, the mechanism is still not clear; further clinical investigations are urgently required.

[1]  David E. Swayne,et al.  Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus , 2006, Nature.

[2]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[3]  Calvin Yu-Chian Chen,et al.  Chemoinformatics and pharmacoinformatics approach for exploring the GABA-A agonist from Chinese herb suanzaoren , 2009 .

[4]  Calvin Yu‐Chian Chen.  A Novel Perspective on Designing the Inhibitor of HER2 Receptor , 2008 .

[5]  A. Lackenby,et al.  Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08 , 2009, Emerging infectious diseases.

[6]  Y. Kaneda,et al.  Development of a transferrin receptor-targeting HVJ-E vector. , 2007, Biochemical and biophysical research communications.

[7]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[8]  P. Palese,et al.  Influenza: old and new threats , 2004, Nature Medicine.

[9]  Yan Li,et al.  Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus , 2007, Nature.

[10]  Alan J. Hay,et al.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.

[11]  Calvin Yu‐Chian Chen.  Insights into the suanzaoren mechanism—From constructing the 3D structure of GABA-A receptor to its binding interaction analysis , 2008 .

[12]  Calvin Yu‐Chian Chen.  Discovery of Novel Inhibitors for c-Met by Virtual Screening and Pharmacophore Analysis , 2008 .

[13]  Calvin Yu-Chian Chen,et al.  Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis , 2009, Acta Pharmacologica Sinica.

[14]  Calvin Yu-Chian Chen,et al.  De novo design of novel selective COX-2 inhibitors: From virtual screening to pharmacophore analysis , 2009 .

[15]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[16]  I. Barr,et al.  Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues. , 2007, Antiviral research.

[17]  Jianguo Wu,et al.  Origin of highly pathogenic H5N1 avian influenza virus in China and genetic characterization of donor and recipient viruses. , 2007, The Journal of general virology.

[18]  Kun-tze Chen,et al.  Novel selective inhibitors of hydroxyxanthone derivatives for human cyclooxygenase-2 , 2007, Acta Pharmacologica Sinica.

[19]  Calvin Yu-Chian Chen,et al.  Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping , 2009 .

[20]  M. Moradi,et al.  Preparation of Neuraminidase-Specific Antiserum from the H9N2 Subtype of Avian Influenza Virus , 2007 .

[21]  Hung-Jin Huang,et al.  Ligand-Based Dual Target Drug Design for H1N1: Swine Flu- A Preliminary First Study , 2009, Journal of biomolecular structure & dynamics.

[22]  Y. Guan,et al.  Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? , 2002, The Lancet.

[23]  Y. Ikehara,et al.  Involvement of a host erythrocyte sialic acid content in Babesia bovis infection. , 2007, The Journal of veterinary medical science.

[24]  L. Raymond,et al.  Treatment of post-influenza pneumonia in health care workers. , 2007, Journal of occupational and environmental medicine.

[25]  Calvin Yu-Chian Chen,et al.  What is the Effective Component in Suanzaoren Decoction for Curing Insomnia? Discovery by Virtual Screening and Molecular Dynamic Simulation , 2008, Journal of biomolecular structure & dynamics.